{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:56:47Z","timestamp":1790708207047,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U10DA013046"],"award-info":[{"award-number":["U10DA013046"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U10DA013035"],"award-info":[{"award-number":["U10DA013035"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1DA013035"],"award-info":[{"award-number":["UG1DA013035"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U10DA013732"],"award-info":[{"award-number":["U10DA013732"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["HHSN271201500065C"],"award-info":[{"award-number":["HHSN271201500065C"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["HHSN271201200017C"],"award-info":[{"award-number":["HHSN271201200017C"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K24 DA022412"],"award-info":[{"award-number":["K24 DA022412"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["contemporaryclinicaltrials.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.cct.2016.08.004","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T10:32:04Z","timestamp":1470911524000},"page":"253-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale"],"prefix":"10.1016","volume":"50","clinical-trial-number":[{"clinical-trial-number":"nct00781898","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02032433","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Joshua D.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Novo","family":"MPA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genie L.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Brigham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lindblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dikla","family":"Shmueli-Blumberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Stablein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rotrosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2016.08.004_bb0005","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2014tackling the opioid-overdose epidemic","volume":"370","author":"Volkow","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2016.08.004_bb0010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/10550881003684798","article-title":"Pharmacotherapy in the treatment of addiction: methadone","volume":"29","author":"Kreek","year":"2010","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.cct.2016.08.004_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub3","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2008","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.cct.2016.08.004_bb0020","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.cct.2016.08.004_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002209.pub2","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"Mattick","year":"2009","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.cct.2016.08.004_bb0030","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/00952990600918973","article-title":"Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?","volume":"32","author":"Nunes","year":"2006","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.cct.2016.08.004_bb0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial","volume":"63","author":"Comer","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.cct.2016.08.004_bb0040","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/archgenpsychiatry.2012.1a","article-title":"Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence","volume":"69","author":"Krupitsky","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.cct.2016.08.004_bb0045","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1176\/appi.ajp.2011.11071121","article-title":"Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial","volume":"169","author":"Tiihonen","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cct.2016.08.004_bb0050","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2016.08.004_bb0055","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.drugalcdep.2011.10.016","article-title":"The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone","volume":"123","author":"Stein","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.cct.2016.08.004_bb0060","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jsat.2006.09.002","article-title":"Client and counselor attitudes toward the use of medications for treatment of opioid dependence","volume":"32","author":"Rieckmann","year":"2007","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.cct.2016.08.004_bb0065","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13722-014-0023-0","article-title":"Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder","volume":"10","author":"Fox","year":"2015","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.cct.2016.08.004_bb0070","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jsat.2011.05.005","article-title":"A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment","volume":"41","author":"Rieckmann","year":"2011","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.cct.2016.08.004_bb0075","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11920-010-0135-5","article-title":"Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available","volume":"12","author":"Krupitsky","year":"2010","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.cct.2016.08.004_bb0080","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jsat.2009.05.004","article-title":"Choosing a control group in effectiveness trials of behavioral drug abuse treatments","volume":"37","author":"Brigham","year":"2009","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.cct.2016.08.004_bb0085","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/00952990.2011.596978","article-title":"Ten take home lessons from the first 10years of the CTN and 10 recommendations for the future","volume":"37","author":"Carroll","year":"2011","journal-title":"Am. J. Drug Alcohol Abuse"},{"issue":"Suppl. 1","key":"10.1016\/j.cct.2016.08.004_bb0090","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.jsat.2010.01.012","article-title":"Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs?","volume":"38","author":"Nunes","year":"2010","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.cct.2016.08.004_bb0095","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/00952990.2011.600386","article-title":"Modeling site effects in the design and analysis of multi-site trials","volume":"37","author":"Feaster","year":"2011","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.cct.2016.08.004_bb0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-clinpsy-032511-143152","article-title":"A \u201cSMART\u201d design for building individualized treatment sequences","volume":"8","author":"Lei","year":"2012","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.cct.2016.08.004_bb0105","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jsat.2013.04.002","article-title":"Perceived relapse risk and desire for medication assisted treatment among persons seeking inpatient opiate detoxification","volume":"45","author":"Bailey","year":"2013","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.cct.2016.08.004_bb0110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jsat.2015.07.002","article-title":"Preferences for aftercare among persons seeking short-term opioid detoxification","volume":"59","author":"Stein","year":"2015","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.cct.2016.08.004_bb0115","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/10550490500528464","article-title":"Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial","volume":"15","author":"Sullivan","year":"2006","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.cct.2016.08.004_bb0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1037\/a0013049","article-title":"Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence","volume":"23","author":"Carpenter","year":"2009","journal-title":"Psychol. Addict. Behav."},{"key":"10.1016\/j.cct.2016.08.004_bb0125","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4088\/JCP.09m05080ecr","article-title":"Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment","volume":"71","author":"Brooks","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.cct.2016.08.004_bb0130","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1360-0443.2005.01154.x","article-title":"A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network","volume":"100","author":"Ling","year":"2005","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2016.08.004_bb0135","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/00952990.2011.653426","article-title":"Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice","volume":"38","author":"Sigmon","year":"2012","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.cct.2016.08.004_bb0140","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jama.294.8.903","article-title":"Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial","volume":"294","author":"Collins","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2016.08.004_bb0145","series-title":"Vivitrol Product Package Insert and Medication Guide","author":"Alkermes","year":"2013"},{"key":"10.1016\/j.cct.2016.08.004_bb0150","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use","volume":"9","author":"Kampman","year":"2015","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.cct.2016.08.004_bb0155","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2016.08.004_bb0160","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S0140-6736(11)61333-0","article-title":"Authors' reply","volume":"378","author":"Wolfe","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2016.08.004_bb0165","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0140-6736(10)62056-9","article-title":"Concerns about injectable naltrexone for opioid dependence","volume":"377","author":"Wolfe","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2016.08.004_bb0170","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.drugalcdep.2007.06.013","article-title":"Management of relapse in naltrexone maintenance for heroin dependence","volume":"91","author":"Sullivan","year":"2007","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.cct.2016.08.004_bb0175","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2016.08.004_bb0180","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11606-008-0866-8","article-title":"Home buprenorphine\/naloxone induction in primary care","volume":"24","author":"Lee","year":"2009","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.cct.2016.08.004_bb0185","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jamainternmed.2014.2556","article-title":"Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial","volume":"174","author":"Liebschutz","year":"2014","journal-title":"JAMA internal medicine"},{"key":"10.1016\/j.cct.2016.08.004_bb0190","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: a systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.cct.2016.08.004_bb0195","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4088\/JCP.11m06837","article-title":"Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk","volume":"72","author":"Trivedi","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.cct.2016.08.004_bb0200","series-title":"Measuring Alcohol Consumption","article-title":"Timeline follow-back: a technique for assessing self-reported alcohol consumption","author":"Sobell","year":"1992"},{"key":"10.1016\/j.cct.2016.08.004_bb0205","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1037\/0022-006X.68.1.134","article-title":"The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties","volume":"68","author":"Fals-Stewart","year":"2000","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.cct.2016.08.004_bb0210","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","article-title":"The fifth edition of the addiction severity index","volume":"9","author":"McLellan","year":"1992","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.cct.2016.08.004_bb0215","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.cct.2016.08.004_bb0220","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/00952998709001515","article-title":"Two new rating scales for opiate withdrawal","volume":"13","author":"Handelsman","year":"1987","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.cct.2016.08.004_bb0225","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00846549","article-title":"Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire","volume":"12","author":"Fagerstrom","year":"1989","journal-title":"J. Behav. Med."},{"key":"10.1016\/j.cct.2016.08.004_bb0230","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","article-title":"The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire","volume":"86","author":"Heatherton","year":"1991","journal-title":"Br. J. Addict."},{"issue":"Suppl. 2","key":"10.1016\/j.cct.2016.08.004_bb0235","first-page":"S281","article-title":"Preparations for AIDS vaccine trials. An automated version of the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors","volume":"10","author":"Navaline","year":"1994","journal-title":"AIDS Research and Human Retroviruses"},{"key":"10.1016\/j.cct.2016.08.004_bb0240","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1017\/S1355617709090626","article-title":"Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition\/interference control, and visuomotor abilities","volume":"15","author":"Sanchez-Cubillo","year":"2009","journal-title":"Journal of the International Neuropsychological Society"},{"key":"10.1016\/j.cct.2016.08.004_bb0245","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/0001-6918(66)90004-7","article-title":"The Stroop color-word test: a review","volume":"25","author":"Jensen","year":"1966","journal-title":"Acta Psychol."},{"key":"10.1016\/j.cct.2016.08.004_bb0250","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann. Med."},{"key":"10.1016\/j.cct.2016.08.004_bb0255","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.drugalcdep.2005.08.012","article-title":"Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population","volume":"82","author":"van der Zanden","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.cct.2016.08.004_bb0260","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/00005650-199907000-00006","article-title":"Accuracy of self-reported health services use and patterns of care among urban older adults","volume":"37","author":"Wallihan","year":"1999","journal-title":"Med. Care"},{"key":"10.1016\/j.cct.2016.08.004_bb0265","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.aje.a115129","article-title":"Agreement between questionnaire data and medical records. The evidence for accuracy of recall","volume":"129","author":"Harlow","year":"1989","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.cct.2016.08.004_bb0270","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/0895-4356(96)00143-6","article-title":"Comparison of self-reported and medical record health care utilization measures","volume":"49","author":"Roberts","year":"1996","journal-title":"J. Clin. Epidemiol."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714416302026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714416302026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T08:56:36Z","timestamp":1536483396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714416302026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":54,"alternative-id":["S1551714416302026"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2016.08.004","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2016.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}